Department of Hematology-Oncology, Mayo Clinic, 13400 East Shea Boulevard, Collaborative Research Building, Room 3-028, Scottsdale, AZ, 85259-5494, USA,
Curr Oncol Rep. 2013 Oct;15(5):450-6. doi: 10.1007/s11912-013-0331-7.
Waldenström's macroglobulinemia (WM) is an indolent but incurable B-cell malignancy. Over the last decade, advances in the molecular field brought about by the use of high-throughput genomic analyses-including array-based comparative genomic hybridization and massively parallel genome sequencing-have considerably improved our understanding of the genetic basis of WM. Its pathogenesis, however, remains fragmented. Important steps have been made in elucidating the underlying aberrations and deregulated mechanisms of the disease, and thereby providing invaluable information for identifying biomarkers for disease diagnosis, risk stratification, and therapeutic approaches. We review the genetic basis of the disease.
华氏巨球蛋白血症（WM）是一种惰性但无法治愈的 B 细胞恶性肿瘤。在过去的十年中，由于高通量基因组分析（包括基于阵列的比较基因组杂交和大规模平行基因组测序）的应用，分子领域的进展极大地提高了我们对 WM 的遗传基础的理解。然而，其发病机制仍然不完整。在阐明疾病的潜在异常和失调机制方面已经取得了重要进展，从而为识别疾病诊断、风险分层和治疗方法的生物标志物提供了宝贵的信息。我们回顾了该疾病的遗传基础。
